NightHawk Biosciences Confirms NHWK Common Stock, Purchase Rights on NYSE American

TL;DR

**NHWK confirms common stock and purchase rights are listed on NYSE American.**

AI Summary

NightHawk Biosciences, Inc. filed an 8-K on January 26, 2024, to update its registered securities. The filing confirms that the company's Common Stock, with a $0.0002 par value per share, is traded under the symbol NHWK on the NYSE American LLC. Additionally, Common Stock Purchase Rights are also registered on the NYSE American LLC, though they do not have a trading symbol. This matters to investors because it clarifies the current listing status of their shares and any associated rights, ensuring transparency regarding where these securities can be bought and sold.

Why It Matters

This filing confirms the current listing of NightHawk Biosciences' common stock and purchase rights on the NYSE American LLC, providing clarity for investors on where their securities are traded.

Risk Assessment

Risk Level: low — This filing is a routine update confirming existing security listings and does not introduce new financial risks.

Analyst Insight

Investors should note this filing as a routine confirmation of listing details, ensuring their records align with the company's registered securities on the NYSE American LLC.

Key Numbers

• $0.0002 — par value per share (for NightHawk Biosciences' Common Stock)

Key Players & Entities

• NightHawk Biosciences, Inc. (company) — registrant
• NYSE American LLC (company) — exchange where securities are registered
• NHWK (company) — trading symbol for Common Stock
• $0.0002 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• NightHawk Biosciences will continue to trade its common stock under the NHWK symbol on the NYSE American LLC. (NightHawk Biosciences, Inc.) — high confidence, target: 2025-01-26

FAQ

Key Financial Figures

• $0.0002 — nge on which registered Common Stock, $0.0002 par value per share NHWK NYSE America

Filing Documents

• nhwk_8k.htm (8-K) — 27KB
• 0001079973-24-000128.txt ( ) — 237KB
• nhwk-20240126.xsd (EX-101.SCH) — 3KB
• nhwk-20240126_def.xml (EX-101.DEF) — 26KB
• nhwk-20240126_lab.xml (EX-101.LAB) — 36KB
• nhwk-20240126_pre.xml (EX-101.PRE) — 25KB
• nhwk_8k_htm.xml (XML) — 5KB

01 Other Items

Item 8.01 Other Items On January 26, 2024, NightHawk Biosciences, Inc. (the "Company") announced that it has determined to effectuate the change of the name of the Company to Scorpius Holdings, Inc. on February 6, 2024. In connection with the name change, the Company's ticker will change to SCPX. The Company is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. The Company will continue to operate its CDMO within the Scorpius BioManufacturing, Inc. subsidiary.

01 Financial Statements and

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 26, 2024 NightHawk Biosciences, Inc. By: /s/ Jeff Wolf Name: Jeff Wolf Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR